Semaglutide race: Torrent grabs 38% market share

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of Novo Nordisk's patent for the innovator molecule in end-March. They generated about ₹44 crore in generic semaglutide sales in April.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MRljJ4P
via IFTTT